LivingGLP1
Study S000371

Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial

Included trial: extracted dataClinicalTrials.gov recordStatistical Analysis Plan (PDF)

Registration

Registration
NCT04122716
Acronym
S-LITE
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
QUADRUPLE
Status
UNKNOWN
Enrollment
215
Start
2016-09
Primary completion
2019-11
Lead sponsor
Signe Torekov
Conditions
Obesity
Interventions
DRUG:Liraglutide; BEHAVIORAL:Exercise
Results posted
FALSE
Secondary identifiers
EUDRACT_NUMBER:2015-005585-32; OTHER:H-16027082; NIH:2015

Registered primary outcomes

  • Body weight change (kg) [Change from baseline to end-of-treatment (52 weeks)]

Linked records (31)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0002886Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.
Jensen SBK, Sports medicine (Auckland, N.Z.)
2026Randomized trialPMID 41579235DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:41579235
R0006966Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial.
Sandsdal RM, Nature metabolism
2026Randomized trialPMID 42342869DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:42342869
R0010447One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.
Holt J, Obesity (Silver Spring, Md.)
2026Randomized trialPMID 40998556DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:40998556
R0023990Weight Loss Induces Changes in Vitamin D Status in Women With Obesity But Not in Men: A Randomized Clinical Trial.
Holt R, The Journal of clinical endocrinology and metabolism
2025Randomized trialPMID 39530599DOIcites ClinicalTrials.gov:NCT04122716; registry reference DERIVED:39530599
R0005690Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.
Jensen SBK, JAMA network open
2024Randomized trialPMID 38916894DOIcites EudraCT:2015-005585-32
R0014026Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial.
Jensen SBK, EClinicalMedicine
2024Randomized trialPMID 38544798DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:38544798
R0007438Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
Sandsdal RM, Cardiovascular diabetology
2023Randomized trialPMID 36841762DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:36841762
R0024305Insufficient sleep predicts poor weight loss maintenance after 1 year.
Bogh AF, Sleep
2023Randomized trialPMID 36472579DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:36472579
R0017418Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?
Doggrell SA, Expert opinion on pharmacotherapy
2022OtherPMID 34913784DOIcites ClinicalTrials.gov:NCT04122716
R0017714Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.
Jensen SBK, Nature communications
2022Randomized trialPMID 35970829DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:35970829
R0018595Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
Andersen E, Human reproduction (Oxford, England)
2022Randomized trialPMID 35580859DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:35580859
R0023498Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR, The New England journal of medicine
2021Randomized trialPMID 33951361DOIcites ClinicalTrials.gov:NCT04122716; cites EudraCT:2015-005585-32; registry reference DERIVED:33951361
R00482952028-P: Adding Exercise to Liraglutide Treatment in Weight Loss Maintenance Abolishes the Increase in Heart Rate Seen with Liraglutide Alone: The S-LITE Randomized Trial
Julie Rehné Lundgren, Diabetes
2020Randomized trialDOIcites ClinicalTrials.gov:NCT04122716
R00501701974-P: Diet-Induced Weight Loss Improves Sleep Quality and These Improvements Are Sustained with One Year of Weight Maintenance with Exercise: The S-LITE Randomized Trial
Charlotte Janus, Diabetes
2020Randomized trialDOIcites ClinicalTrials.gov:NCT04122716
R0011056Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.
Jensen SBK, BMJ open
2019ProtocolPMID 31678947DOIcites EudraCT:2015-005585-32
R0009447Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
Torekov SS, Cardiovascular research
2018OtherPMID 30052921DOIregistry reference BACKGROUND:30052921
R0014212Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation.
Garczorz W, Cardiovascular therapeutics
2018OtherPMID 29283509DOIregistry reference BACKGROUND:29283509
R0020247GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
Pastel E, Clinical science (London, England : 1979)
2017Randomized trialPMID 28049736DOIregistry reference BACKGROUND:28049736
R0022060Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27295427DOIregistry reference BACKGROUND:27295427
R0022278Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27633186DOIregistry reference BACKGROUND:27633186
R0018258Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
Iepsen EW, International journal of obesity (2005)
2015Randomized trialPMID 25287751DOIregistry reference BACKGROUND:25287751
R0022927A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, The New England journal of medicine
2015Randomized trialPMID 26132939DOIregistry reference BACKGROUND:26132939
R0025894Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ, JAMA
2015Randomized trialPMID 26284720DOIregistry reference BACKGROUND:26284720
R0021526Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.
Hogan AE, Diabetologia
2014PreclinicalPMID 24362727DOIregistry reference BACKGROUND:24362727
R0019576A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Noyan-Ashraf MH, Circulation
2013PreclinicalPMID 23186644DOIregistry reference BACKGROUND:23186644
R0023762Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
Wadden TA, International journal of obesity (2005)
2013Randomized trialPMID 23812094DOIregistry reference BACKGROUND:23812094
R0024181Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.
Lee YS, Diabetologia
2012PreclinicalPMID 22722451DOIregistry reference BACKGROUND:22722451
R0026878Exenatide exerts a potent antiinflammatory effect.
Chaudhuri A, The Journal of clinical endocrinology and metabolism
2012Randomized trialPMID 22013105DOIregistry reference BACKGROUND:22013105
R0014510Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Arakawa M, Diabetes
2010PreclinicalPMID 20068138DOIregistry reference BACKGROUND:20068138
R0027078Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.
Bunck MC, Diabetes care
2010Randomized trialPMID 20424219DOIregistry reference BACKGROUND:20424219
R0030506Glucagon-like peptide-1, glucose homeostasis and diabetes.
Holst JJ, Trends in molecular medicine
2008Narrative reviewPMID 18353723DOIregistry reference BACKGROUND:18353723